Sponsor

Novartis Pharma AG

Lichtstrasse 35, 4056

About the sponsor

Novartis Pharma AG funds a broad oncology portfolio spanning solid tumours and blood cancers, with particular interest in breast cancer, prostate cancer, lung cancer, colorectal cancer, ovarian cancer, melanoma, and glioblastoma. Its studies also extend across lymphoma, leukemia, multiple myeloma, and other advanced malignancies.

Advanced solid tumours
Breast and prostate cancers
Lymphoma and leukemia
Glioblastoma and melanoma

The trial portfolio includes cancers defined by molecular features such as KRAS G12C, PIK3CA, EGFR, BRAF, IDH1, and PSMA expression, alongside radioligand and immunotherapy-related research in metastatic disease.

About Specializations

Novartis Pharma AG runs clinical trials in conditions such as Non-small cell lung cancer, Arteriosclerosis, Sjogren's syndrome, Chronic myeloid leukaemia, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

195 clinical trials

Papulopustular rosacea

Recruiting

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

Registered drugNo placebo

Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dimeticone
Sponsor:Novartis Pharma AG

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Emtricitabine
Sponsor:Novartis Pharma AG

Contact Research Centre

Sjogren's syndrome

Recruiting

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Emtricitabine
Sponsor:Novartis Pharma AG

Contact Research Centre

Coronary artery disease+2

Recruiting

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Investigational

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Novartis Pharma AG

Contact Research Centre

Huntington's disease

Recruiting

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Votoplam
Sponsor:Novartis Pharma AG

Contact Research Centre

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Novartis Pharma AG

Contact Research Centre

Asthma

Recruiting

Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

Registered drug